New Approaches in Nanomedicine for Ischemic Stroke
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10347/26254
Files in this item
Metadata
Title: | New Approaches in Nanomedicine for Ischemic Stroke |
Author: | Correa Paz, Clara Silva Candal, Andrés da Polo Tobajas, Ester Parcq, Jerome Vivien, Denis Maysinger, Dusica Pelaz García, Beatriz Campos Pérez, Francisco |
Affiliation: | Universidade de Santiago de Compostela. Centro de Investigación en Química Biolóxica e Materiais Moleculares Universidade de Santiago de Compostela. Departamento de Física de Partículas Universidade de Santiago de Compostela. Departamento de Química Inorgánica |
Subject: | Cell tracking | Diagnosis | Drug carriers | Drug control release | Nanomedicine | Neuroprotection | Recovery | Stroke | Tissue plasminogen activator | |
Date of Issue: | 2021 |
Publisher: | MDPI |
Citation: | Pharmaceutics 2021, 13(5), 757; https://doi.org/10.3390/pharmaceutics13050757 |
Abstract: | Ischemic stroke, caused by the interruption of blood flow to the brain and subsequent neuronal death, represents one of the main causes of disability in developed countries. Therapeutic methods such as recanalization approaches, neuroprotective drugs, or recovery strategies have been widely developed to improve the patient’s outcome; however, important limitations such as a narrow therapeutic window, the ability to reach brain targets, or drug side effects constitute some of the main aspects that limit the clinical applicability of the current treatments. Nanotechnology has emerged as a promising tool to overcome many of these drug limitations and improve the efficacy of treatments for neurological diseases such as stroke. The use of nanoparticles as a contrast agent or as drug carriers to a specific target are some of the most common approaches developed in nanomedicine for stroke. Throughout this review, we have summarized our experience of using nanotechnology tools for the study of stroke and the search for novel therapies |
Publisher version: | https://doi.org/10.3390/pharmaceutics13050757 |
URI: | http://hdl.handle.net/10347/26254 |
DOI: | 10.3390/pharmaceutics13050757 |
E-ISSN: | 1999-4923 |
Rights: | © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/) Atribución 4.0 Internacional |
Collections
-
- CIQUS-Artigos [404]
- FP-Artigos [409]
- QI-Artigos [45]
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)